Africa-Europe partnership launches study to evaluate emergency response tools for severe malaria in highly isolated rural settings 27 November 2023
First African-manufactured combination therapy for seasonal malaria chemoprevention receives WHO prequalification 6 November 2023 Universal Corporation Ltd (UCL), a Strides Pharma Science Limited (Strides) enterprise, with support from MMV, has become the first African manufacturer to gain WHO prequalification for their sulfadoxine-pyrimethamine + amodiaquine product.
7 MMV funded scholars will start their training at the Malaria Research and Training Center, Mali 2 October 2023
SMC and RTS,S vaccine in combination show considerable advantage in preventing malaria 31 August 2023
Brazil becomes the first malaria-endemic country to register single-dose tafenoquine for children with relapsing malaria 21 August 2023
MMV receives rank of “very high performer” in 2023 Global Health 50/50 report for 2nd year 27 July 2023
MMV awards Dr Stephen Brand-led team for developing innovative dose prediction tool 'MMVSola' 27 June 2023
Brazil becomes the first malaria-endemic country to adopt single-dose tafenoquine and STANDARD G6PD Test for the treatment of relapsing Plasmodium vivax malaria 6 June 2023
MMV mourns the loss of Pascoal Mocumbi, former Mozambican prime minister and EDCTP High Representative 31 March 2023
MMV welcomes appointment of Dr Daniel Ngamije as Director of Global Malaria Control Programme 29 March 2023
MMV’s film on real-world tafenoquine study wins advocacy award at the 7th annual ISNTD festival 28 March 2023
MMV ESAC member Dennis Smith recognized by the International Society for the Study of Xenobiotics 28 February 2023
